Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. (vol 369, pg 559, 2007)

被引：0

|

作者：

Coombes, R. C.

Kilburn, L. S.

Snowdon, C. F.

机构：

来源：

LANCET | 2007年 / 369卷 / 9565期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：906 / 906

页数：1

相关论文

共 41 条

[31] Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial (vol 14, pg 989, 2013)
Johnston, S. R. D.
Kilburn, L. S.
Ellis, P.
LANCET ONCOLOGY, 2013, 14 (10): : E391 - E391
[32] Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. (vol 374, pg 210, 2009)
Smolen, J. S.
Kay, J.
Doyle, M. K.
LANCET, 2009, 374 (9699): : 1422 - 1422
[33] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2019, 20 (10): : E559 - E559
[34] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
[35] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
Motzer, R. J.
Rini, B., I
McDermott, D. F.
LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
[36] NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial (vol 20, pg 1148, 2019)
Bonvalot, S.
Rutkowski, P. L.
Thariat, J.
LANCET ONCOLOGY, 2019, 20 (09): : E468 - E468
[37] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial (vol 376, pg 687, 2010)
Bang, Y-J
Van Cutsem, E.
Feyereislova, A.
LANCET, 2010, 376 (9749): : 1302 - 1302
[38] Early Versus Delayed Endocrine Treatment of T2-T3 pN1-3 M0 Prostate Cancer Without Local Treatment of the Primary Tumour: Final Results of European Organisation for the Research and Treatment of Cancer Protocol 30846 After 13 Years of Follow-up (A Randomised Controlled Trial)
Schroder, Fritz H.
Kurth, Karl-Heinz
Fossa, Sophie D.
Hoekstra, Wytse
Karthaus, Peter P.
De Prijck, Linda
Collette, Laurence
EUROPEAN UROLOGY, 2009, 55 (01) : 14 - 22
[39] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 431, 2016)
Cristofanilli, M.
Turner, N. C.
Bondarenko, I
LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
[40] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (vol 17, pg 425, 2016)
Cristofanilli, M.
Turner, N. C.
Bondarenko, I
LANCET ONCOLOGY, 2016, 17 (04): : E136 - E136

← 1 2 3 4 5 →